PEGylated Poly(Amine-Co-Ester) Polyplexes for Stable Pulmonary Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral vectors for gene delivery, such as cationic lipids and polymers, face challenges including instability in physiological fluids, aggregation, and high toxicity, limiting their clinical applicability and efficiency for systemic and pulmonary delivery of nucleic acids.
Innovation Solution
Development of poly(amine-co-ester) polymers with modified end groups that form stable polyplexes, enhancing cellular uptake and transfection efficiency while reducing toxicity, particularly suitable for pulmonary delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic lipids or polymers are used as non-viral vectors for gene delivery, then DNA condensation and cellular uptake are facilitated, but stability in physiological fluids deteriorates causing complex breakdown or aggregation
Solution Approach 1:
The patent modifies the physical and chemical parameters of the cationic polymer by introducing polyethylene glycol (PEG) side chains of specific lengths (2k, 5k, or 10k Daltons) and controlling the polymer's molecular weight (2k-20k Daltons). These parameter changes create steric stabilization that prevents aggregation in physiological fluids while maintaining DNA condensation capability, directly resolving the contradiction between stability and aggregation.
Solution Approach 2:
The invention creates a composite structure where PEG side chains are grafted onto the cationic polymer backbone. This composite material combines the DNA-binding capability of cationic groups with the steric stabilization and hydrophilicity of PEG chains, enabling both stable circulation in blood and effective gene delivery, thus resolving the stability-aggregation contradiction.
2Reliability
If cationic vectors with excess positive charge are used to achieve transfection, then cellular uptake and transfection efficiency are improved, but toxicity increases due to interactions with cellular components
Solution Approach 1:
The patent optimizes the charge density parameter by controlling the polymer's molecular weight (2k-20k Daltons) and PEG content, creating a balance where sufficient positive charges remain for DNA condensation and cellular uptake while reducing excess charge that causes toxic interactions with cell membranes and proteins. This parameter optimization directly addresses the transfection efficiency-toxicity contradiction.
Solution Approach 2:
The PEG side chains are distributed along the polymer backbone, creating local hydrophilic zones that reduce the overall interaction between the cationic polymer and cellular components. This local modification maintains transfection capability at the DNA-polymer interface while reducing toxicity at the polymer-cell membrane interface.
3Reliability
If polymer molecular weight is increased to improve polyplex stability, then stability improves, but productivity of intracellular release and transfection may deteriorate
Solution Approach 1:
The patent identifies and optimizes the molecular weight parameter within a specific range (2k-20k Daltons), finding that this range provides the optimal balance between polyplex stability and intracellular release efficiency. Polymers in this range form stable polyplexes that protect DNA during circulation while maintaining sufficient flexibility and degradation capability for effective intracellular release and transfection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymers demonstrate improved loading, cellular transfection, and intracellular endosomal release of nucleic acids, with reduced toxicity and preferential uptake in specific tissues, especially when administered via the pulmonary route.
Implementation Method 1
Both cationic lipid and cationic polymer systems deliver genes by forming condensed complexes with negatively charged DNA through electrostatic interactions
Implementation Method 2
Polyethylene glycol (PEG) side chains have been shown to stabilize cationic polymers and polyplexes
Data Source
AI summary
Poly(amine-co-ester) polymers, methods of forming active agent-load polyplexes and particles therefrom, and methods of using them for delivery of nucleic acid agents with optimal uptake have been developed. Examples demonstrate critical molecular weights in combination with exposed carboxylic and/or hydroxyl groups, and methods of making. Typically, the compositions are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the compositions are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition. For poly(amine-co-ester) polymers with specific amine or hydroxyl group containing end-groups in admixture with PEGylated poly(amine-co-ester) polymers, in vivo delivery to the lung by inhalation has been shown.